ADPT
Adaptive Biotechnologies
NASDAQ · Life Sciences Tools & Services
$15.77
-0.70 (-4.25%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 185.73M | 176.77M | 1.12B | 1.18B | 1.15B |
| Net Income | -165,519,595 | -141,779,418 | 147.55M | 166.04M | 120.97M |
| EPS | — | — | — | — | — |
| Profit Margin | -89.1% | -84.7% | 13.2% | 14.0% | 10.5% |
| Rev Growth | +5.1% | +5.1% | +15.4% | +9.0% | -7.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 477.51M | 477.51M | 561.67M | 456.20M | 455.55M |
| Total Equity | 726.25M | 726.25M | 1.53B | 1.50B | 1.38B |
| D/E Ratio | 0.66 | 0.66 | 0.37 | 0.30 | 0.33 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -157,977,935 | -142,837,192 | 188.86M | 190.10M | 191.59M |
| Free Cash Flow | — | — | 144.75M | 135.00M | 109.51M |